A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands

Journal of Travel Medicine

Volumn 21, Issue 6, 2014, Pages 421-424

  van de Pol, Eva M ^a   Gisolf, Elizabeth H ^a   Richter, Clemens ^a  

^a RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANALGESIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A HEPATITIS B VACCINE; INFUSION FLUID; YELLOW FEVER VACCINE; LIVE VACCINE;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; DUTCHMAN; GAMBIA; HEADACHE; HEPATOMEGALY; HUMAN; HYPERTRANSAMINASEMIA; HYPONATREMIA; JAUNDICE; LYMPHOCYTOPENIA; MALAISE; MALE; MYALGIA; NAUSEA; REAL TIME POLYMERASE CHAIN REACTION; SPLENOMEGALY; THROMBOCYTOPENIA; TRAVEL; VACCINATION REACTION; VIRUS LOAD; VISCEROTROPIC DISEASE; IMMUNOLOGY; MULTIPLE ORGAN FAILURE; NETHERLANDS; REMISSION; VIROLOGY; YELLOW FEVER;

ABDOMINAL PAIN; ADULT; HEADACHE; HUMANS; MALE; MULTIPLE ORGAN FAILURE; NAUSEA; NETHERLANDS; REMISSION, SPONTANEOUS; TRAVEL; VACCINES, ATTENUATED; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84934267650     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/jtm.12135     Document Type: Article

References (20)

1. Monath TP. Yellow fever: an update. Lancet Infect Dis 2001; 1:11-20.
2. Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommn Rep 2010; 59:1-27.
3. Centers for Disease Control and Prevention. CDC health information for international travel 2014. New York: Oxford University Press, 2014.
4. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26:6077-6082.
5. Monath TH, Cetron MS, Teuwen D. Yellow fever. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines. Philadelphia: Saunders/Elsevier, 2008:959-1055.
6. Chan RC, Penney DJ, Little D, et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001; 358:121-122.
7. Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001; 358:98-104.
8. Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001; 358:91-97.
9. Gershman MD, Staples JE, Bentsi-Enchill AD, et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2012; 30:5038-5058.
10. Thomas RE, Spragins W, Lorenzetti DL. How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria? Vaccine 2013; 31:6201-6209.
11. Engel AR, Vasconcelos PFC, McArthur MA, Barrett AD. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 2006; 24:2803-2809.
12. Khromova AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as risk factor for serious adverse events. Vaccine 2005; 23:3256-3263.
13. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17 D yellow fever vaccine, ARILVAX. Vaccine 2004; 22:2103-2105.
14. Martin M, Weld LH, Tsai TF, et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001; 7:945-951.
15. Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell Q Rep 2004; 28:244-248.
16. Barwick R. History of thymoma and yellow fever vaccination. Lancet 2004; 36:936.
17. Whittembury A, Ramirez G, Hernández H, Repero AM, et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009; 27:5974-5981.
18. Reinhardt B, Jaspert R, Niedrig M, et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998; 56:159-167.
19. Dos Santos AP, Bertho AL, Dias DC, et al. Lymphocyte subset analysis in healthy adults vaccinated with yellow fever 17DD virus. Mem Inst Oswaldo Cruz 2005; 100:331-337.
20. Belsher JL, Gay P, Brinton M, et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007; 25:8480-8485.